Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Completed

Conditions studied: Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Neoplasm, Mast Cell Leukemia

In brief

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

Key facts

Study ID

NCT04695431

Run by

Blueprint Medicines Corporation

People needed

317

Starts

2020-12-02

Expected to finish

2021-10-04

Last updated by the study team

2022-01-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Standford Cancer Center — Palo Alto, California, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Medizinische Universitat Wien — Vienna, Austria
• Universitatmedizin Mannheim — Mannheim, Baden-Wurttemberg, Germany
• Hospital Virgen del Valle — Toledo, Spain
• Guy's and St. Thomas' NHS Foundation Trust — London, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.